雌激素对脑梗塞的神经保护作用及机制
摘要
目的：
通过测定临床脑梗塞患者及局灶性脑缺血再灌注损伤大鼠血清雌激素(Estrogen, E2)、瘦素(Leptin, LEP)、白介素-6(Interleukin-6, IL-6)、可溶性细胞间粘附分子-1(Soluble intercellular adhesion molecule1, sICAM-1)、总胆固醇(Total Cholesterol, TC)、甘油三酯(Triglyceride, TG)、高密度脂蛋白(High-density lipoprotein, HDL)、低密度脂蛋白(Low-density lipoprotein, LDL)及血浆同型半胱氨酸(Homocysteine, HCY)表达水平；检测血清及脑脊液淀粉样蛋白(β-Amyloid protein,β-AP)水平；检测脑梗塞患者血管相关指标包括双侧颈总动脉及双侧颈内动脉的峰值流速(PSV)、双侧颈动脉内膜-中膜厚度(IMT)及左、右侧颈动脉斑块crouse积分；检测大鼠局部脑组织凋亡抑制蛋白B细胞淋巴瘤/白血病-2因子(B-cell lymphoma/Leukemia-2, Bcl-2);并分析E2与这些指标的相关性,全面评价雌激素对脑梗塞的神经保护作用,为临床早期诊断和有效治疗奠定基础。
方法：
分批次选择神经内科住院的发病在24小时以内的急性脑梗塞患者,男女不限,经颅脑CT和/或MRI证实诊断,并按照全国第四届脑血管病会议的诊断标准确诊,同时排除自身免疫性疾病、原发感染性疾病、恶性肿瘤、外伤等可能影响。所有急性脑梗塞患者于入院第2-3天经颅脑CT复查,并参照多田氏公式计算脑梗塞体积,根据具体研究要求进行分组,同时设同期住院的其他无关疾病患者或健康体检者为对照组。建立大鼠局灶性脑缺血再灌注(MCAO)作为急性脑梗塞动物模型,研究雌激素对其的保护作用。
常规方法测定脑梗塞病人及大鼠血清TC、TG、HDL及LDL水平；放射免疫法检测血清E2水平；酶联免疫吸附法(ELISA)检测血清LEP、IL-6及sICAM-1水平；荧光偏振免疫技术(FPIA)检测血浆HCY水平；ELISA检测血清及脑脊液p-AP水平；免疫组化检测E2对局灶性脑缺血再灌注大鼠Bcl-2蛋白的表达的影响。
结果：
1.临床脑梗塞患者血清E2及其它各指标水平的变化
①与对照组相比,脑梗塞组E2水平降低,且脑梗塞体积和血清E2水平呈负相关(P<0.05)；女性脑梗塞患者血清E2水平与糖尿病、酗酒有关系,有糖尿病、酗酒者血清E2水平较无糖尿病、酗酒者为低(P<0.05或P<0.01)。
②与对照组相比,脑梗塞组PSV、IMT及左、右侧颈动脉斑块crouse积分均数均显著高于正常对照组(P<0.05)。
③与对照组相比,脑梗塞组血清LEP、IL-6及sICAM-1水平明显升高(P<0.05或P<0.01)。其中,血清sICAM-1及IL-6水平与脑梗塞病情及病灶大小密切相关；急性期患者血清sICAM-1及IL-6水平远高于缓解期(P<0.05或P<0.01)；大病灶组患者血清sICAM-1及IL-6水平远高于小病灶组(P<0.05或P<0.01)；此外,脑梗塞患者血清sICAM-1含量与高血压、糖尿病有关系,有高血压、糖尿病者血清sICAM-1含量较无高血压、糖尿病者为(P<0.05)。
④与对照组相比,脑梗塞组血清TC、TG及LDL水平明显升高,HDL水平明显降低(P<0.05或P<0.01)。
⑤与对照组相比,脑梗塞组血清HCY含量明显升高(P<0.01)；血浆HCY水平存在性别差异,男性脑梗塞患者HCY水平远高于女性患者(P<0.01)。
⑥与对照组相比,脑梗塞组血清中p-AP含量无明显变化(P>0.05)；但脑脊液中p-AP含量显著升高(P<0.05)。
2.临床脑梗塞患者血清E2与其它各指标的相关性分析
脑梗塞患者血清E2水平与血清LEP、IL-6、sICAM-1、TG、HCY及斑块crouse积分呈负相关关系；与血清HDL呈正相关关系；与脑脊液中β-AP水平呈负相关关系(P<0.05或P<0.01)。
3.各组大鼠(对照组、MCAO组及雌激素治疗组)血清E2及其它各指标水平的变化
与对照组相比,MCAO组血清E2、TC、TG、LDL水平无明显变化(P>0.05)、LEP、IL-6、sICAM-1、HCY及p-AP水平明显升高,HDL水平明显降低,脑脊液p-AP水平亦明显升高,差异均有统计学意义(P<0.05或P<0.01)；与MACO组相比,雌激素治疗组血清TC、TG、LDL水平无明显变化,E2及HDL水平明显升高,LEP、IL-6、 sICAM-1、HCY及p-AP水平明显降低,脑脊液p-AP水平亦明显降低,差异均有统计学意义(P<0.05或P<0.01)。
4.大鼠血清E2水平与其它各指标的相关性分析
大鼠血清E2水平与LEP、IL-6、sICAM-1、HCY、血清p-AP及脑脊液p-AP呈负相关(P<0.05)；与HDL呈正相关(P<0.05)。
5.雌激素治疗对脑缺血大鼠脑梗塞体积及Bcl-2表达的影响
与去卵巢局灶性脑缺血再灌注大鼠比较,雌激素治疗组大鼠其脑梗塞体积明显缩小,且Bcl-2表达水平显著增高(P<0.05)。结论：
1.急性脑梗塞患者血清E2水平较对照组显著降低,E2为脑梗塞患者的保护性因素；急性脑梗塞患者血清LEP、IL-6、sICAM-1、 HCY及脑脊液p-AP较对照组显著上升,LEP、IL-6、sICAM-1、HCY及脑脊液p-AP为脑梗塞患者的危险性因素；E2水平与脑梗塞多个危险因素密切相关,E2在一定程度上可反应脑梗塞病情程度及治疗反应情况。
2.雌激素治疗可有效缩小局灶性脑缺血再灌注大鼠脑梗塞体积,降低机体炎症反应、改善机体脂质及蛋白质代谢水平并发挥缺血脑保护作用,其机制可能与上调脑缺血再灌注后Bcl-2的表达有关,以上为临床脑梗塞的早期干预治疗奠定理论基础。
Objective
To determine the serum level of estrogen (E2), leptin (LEP), interleukin-6(IL-6), soluble intercellular adhesion molecule-1(sICAM-1), total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL), low density lipoprotein Cholesterol (LDL) and homocysteine (HCY) in clinical patients with cerebral infarction and rats with focal cerebral ischemia-reperfusion injury; detect the level of amyloid protein (β-AP) in the serum and cerebrospinal fluid; detect some vascular related indicators including bilateral common carotid artery and the bilateral internal carotid artery peak flow velocity (PSV), bilateral carotid intima-film thickness (IMT) and the left and right carotid plaques crouse score in clinical patients with cerebral infarction; detect the level of Bel-2in local brain tissue of rats with focal cerebral ischemia-reperfusion injury. Analysis whether serum level of estrogen correlated to these indicators, then evaluate the protective effects of estrogen on brain infarction, and finally provide proof for early diagnosis and effective treatment of for clinical brain infarction patients.
Methods
Chose those acute cerebral infarction patients arrived in neurology within24hours after the onset of disease. Diagnosis wasconfirmed by craniocerebral CT and/or MRI, and it was also diagnosed according to the diagnostic criteria of the fourth national cerebrovascular disease conference. At the same time, some complications such as eliminate infectious diseases, autoimmune diseases, primary malignant tumor, and trauma were excluded. All patients with acute cerebral infarction were reviewed craniocerebral CT in2-3days after the admission, and the cerebral infarction volume were calculated by consult chef formula. Patients were grouped according to the needs of specific designs; a control group was conducted at the same time in the same period in the hospital patients. Rats with focal cerebral ischemia reperfusion (MCAO) were conducted as the animal model to study the protective effects of estrogen on acute cerebral infarction.
Serum levels of TC, TG, HDL and LDL in patients and rats were determined in a conventional method; the serum E2level was detected by radioimmunoassay; to detect Serum levels of LEP, IL-6and sICAM-1levels were detected by enzyme-linked immunosorbent (ELISA); plasma HCY levels were detected by Fluorescence polarization immunoassay (FPIA); levels ofβ-AP in serum and cerebrospinal fluid were detected by ELISA; expression of Bel-2protein was determined by immunohistochemical detection.
Results
1. Changes of serum E2and other index levels in clinical patients with cerebral infarction
(1) Compared with the control group, the E2levels decreased in the cerebral infarction group; the cerebral infarction volume and was negatively correlated with serum E2levels (P<0.05); serum E2levels in cerebral infarction patients are associated with diabetes, alcoholism, serum E2levels are lower in those diabetes and alcoholism patients than those without diabetes and alcoholism (P<0.05or P<0.01).
(2) Compared with the control group, the PSV, IMT and plaques crouse scores were significantly higher in the cerebral infarction group (P <0.05).
(3) Compared with the control group, the serum levels of LEP, il-6and sICAM1in the cerebral infarction group increased significantly (P<0.05or P<0.01). Among them, the serum levels of sICAM1and IL-6in the cerebral infarction group are closely related to the disease severity and the size of the lesions; serum levels of sICAM-1and IL-6in those patients under acute phase state is much far higher than those of remission (P<0.05or P<0.01); serum levels of sICAM-1and IL-6is far more higher in patients with large size lesion than those patients with small size lesion (P<0.05or P<0.01); In addition, serum levels of sICAM1in patients with cerebral infarction are associated with high blood pressure, diabetes, serum sICAM1levels are much higher in those patients with high blood pressure and diabetes than those without high blood pressure and diabetes (P<0.05or P<0.01).
(4) Compared with the control group, serum TC, TG and LDL levels in the cerebral infarction group increased significantly, while HDL levels decreased significantly (P<0.05or P<0.01).
(5) Compared with the control group, the serum HCY levels in the cerebral infarction group increased significantly (P<0.01); and there is gender differences in plasma HCY levels, plasma HCY levels in male patients was much higher than female patients (P<0.01).
(6) Compared with the control group, the serum β-AP levels reveled no obviously change in the cerebral infarction group (P>0.05); whileβ-AP levels in cerebrospinal fluid was significantly increased in the cerebral infarction group (P<0.05).
2. Correlation analysis of Serum levels of E2and other index levels in clinical patients with cerebral infarction
Serum levels of E2was negatively related to serum LEP, IL-6, sICAM-1TG, HCY and plaques crouse scores; serum levels of E21was positively correlated with the serum HDL; and negatively correlated with p-AP levels in cerebrospinal fluid (P<0.05or P<0.01).
3. Changes of serum E2and other index levels in rats (control group, MCAO group and estrogen treatment group)
Compared with the control group, serum levels of E2, TC, TG, LDL in rats of MCAO group revealed no obvious changes (P>0.05); serum levels of LEP, il-6, sICAM-1, HCY and obviously increased; while HDL levels significantly decreased; levels of β-AP in cerebrospinal fluid also significantly increased (P<0.05or P<0.01). Compared with the MACO group, serum levels of TC, TG, LDL in the estrogen therapy group revealed no obvious changes (P>0.05); serum levels of E2and HDL levels increased significantly; serum levels of LEP, il-6, sICAM-1, HCY andβ-AP significantly decreased; levels of β-AP in cerebrospinal fluid also significantly decreased (P<0.05or P<0.01).
4. Correlation analysis of Serum levels of E2and other index levels in rats
Serum levels of E2in rats was negatively related to serum LEP, il-6, sICAM-1, HCY, β-AP andβ-AP levels in cerebrospinal fluid (P<0.05); and were positively correlated with serum HDL (P<0.05).
5. The impact on infarction volume of estrogen therapy in rats with focal cerebral ischemia-reperfusion injury and its relation with Bcl-2expression
Compared to the MCAO group, the cerebral infarction volume significantly narrowed in rats of estrogen treatment group; and the expression of Bcl-2significantly increased (P<0.05).
Conclusions
1. Serum levels of E2in patients with acute cerebral infarction significantly decreased than control group and E2was a protective factor for patients with cerebral infarction; Serum levels of LEP, il-6, sICAM-1, HCY and β-AP levels in cerebrospinal fluid in patients with acute cerebral infarction significantly increased than control group and LEP, il-6, sICAM-1, HCY andβ-AP were risk factors for patients with cerebral infarction patients; E2levels were closely associated with multiple risk factors in patients with cerebral infarction, and to some extent E2could reflect the disease severity and response after certain treatment in patients with cerebral infarction.
2. Estrogen therapy could effectively narrow the infarction volume in rats after focal cerebral ischemia reperfusion injury, reduce the inflammatory reaction, improve body lipid and protein metabolism and regulate cell apoptosis, and then play an important role on neural protection in rats with cerebral infarction. Its mechanism may be related to that estrogen could increase the expression of Bel-2after cerebral ischemia reperfusion. This study provided some theoretical basis on estrogen intervention for clinical patients with cerebral infarction.
通过测定临床脑梗塞患者及局灶性脑缺血再灌注损伤大鼠血清雌激素(Estrogen, E2)、瘦素(Leptin, LEP)、白介素-6(Interleukin-6, IL-6)、可溶性细胞间粘附分子-1(Soluble intercellular adhesion molecule1, sICAM-1)、总胆固醇(Total Cholesterol, TC)、甘油三酯(Triglyceride, TG)、高密度脂蛋白(High-density lipoprotein, HDL)、低密度脂蛋白(Low-density lipoprotein, LDL)及血浆同型半胱氨酸(Homocysteine, HCY)表达水平；检测血清及脑脊液淀粉样蛋白(β-Amyloid protein,β-AP)水平；检测脑梗塞患者血管相关指标包括双侧颈总动脉及双侧颈内动脉的峰值流速(PSV)、双侧颈动脉内膜-中膜厚度(IMT)及左、右侧颈动脉斑块crouse积分；检测大鼠局部脑组织凋亡抑制蛋白B细胞淋巴瘤/白血病-2因子(B-cell lymphoma/Leukemia-2, Bcl-2);并分析E2与这些指标的相关性,全面评价雌激素对脑梗塞的神经保护作用,为临床早期诊断和有效治疗奠定基础。
方法：
分批次选择神经内科住院的发病在24小时以内的急性脑梗塞患者,男女不限,经颅脑CT和/或MRI证实诊断,并按照全国第四届脑血管病会议的诊断标准确诊,同时排除自身免疫性疾病、原发感染性疾病、恶性肿瘤、外伤等可能影响。所有急性脑梗塞患者于入院第2-3天经颅脑CT复查,并参照多田氏公式计算脑梗塞体积,根据具体研究要求进行分组,同时设同期住院的其他无关疾病患者或健康体检者为对照组。建立大鼠局灶性脑缺血再灌注(MCAO)作为急性脑梗塞动物模型,研究雌激素对其的保护作用。
常规方法测定脑梗塞病人及大鼠血清TC、TG、HDL及LDL水平；放射免疫法检测血清E2水平；酶联免疫吸附法(ELISA)检测血清LEP、IL-6及sICAM-1水平；荧光偏振免疫技术(FPIA)检测血浆HCY水平；ELISA检测血清及脑脊液p-AP水平；免疫组化检测E2对局灶性脑缺血再灌注大鼠Bcl-2蛋白的表达的影响。
结果：
1.临床脑梗塞患者血清E2及其它各指标水平的变化
①与对照组相比,脑梗塞组E2水平降低,且脑梗塞体积和血清E2水平呈负相关(P<0.05)；女性脑梗塞患者血清E2水平与糖尿病、酗酒有关系,有糖尿病、酗酒者血清E2水平较无糖尿病、酗酒者为低(P<0.05或P<0.01)。
②与对照组相比,脑梗塞组PSV、IMT及左、右侧颈动脉斑块crouse积分均数均显著高于正常对照组(P<0.05)。
③与对照组相比,脑梗塞组血清LEP、IL-6及sICAM-1水平明显升高(P<0.05或P<0.01)。其中,血清sICAM-1及IL-6水平与脑梗塞病情及病灶大小密切相关；急性期患者血清sICAM-1及IL-6水平远高于缓解期(P<0.05或P<0.01)；大病灶组患者血清sICAM-1及IL-6水平远高于小病灶组(P<0.05或P<0.01)；此外,脑梗塞患者血清sICAM-1含量与高血压、糖尿病有关系,有高血压、糖尿病者血清sICAM-1含量较无高血压、糖尿病者为(P<0.05)。
④与对照组相比,脑梗塞组血清TC、TG及LDL水平明显升高,HDL水平明显降低(P<0.05或P<0.01)。
⑤与对照组相比,脑梗塞组血清HCY含量明显升高(P<0.01)；血浆HCY水平存在性别差异,男性脑梗塞患者HCY水平远高于女性患者(P<0.01)。
⑥与对照组相比,脑梗塞组血清中p-AP含量无明显变化(P>0.05)；但脑脊液中p-AP含量显著升高(P<0.05)。
2.临床脑梗塞患者血清E2与其它各指标的相关性分析
脑梗塞患者血清E2水平与血清LEP、IL-6、sICAM-1、TG、HCY及斑块crouse积分呈负相关关系；与血清HDL呈正相关关系；与脑脊液中β-AP水平呈负相关关系(P<0.05或P<0.01)。
3.各组大鼠(对照组、MCAO组及雌激素治疗组)血清E2及其它各指标水平的变化
与对照组相比,MCAO组血清E2、TC、TG、LDL水平无明显变化(P>0.05)、LEP、IL-6、sICAM-1、HCY及p-AP水平明显升高,HDL水平明显降低,脑脊液p-AP水平亦明显升高,差异均有统计学意义(P<0.05或P<0.01)；与MACO组相比,雌激素治疗组血清TC、TG、LDL水平无明显变化,E2及HDL水平明显升高,LEP、IL-6、 sICAM-1、HCY及p-AP水平明显降低,脑脊液p-AP水平亦明显降低,差异均有统计学意义(P<0.05或P<0.01)。
4.大鼠血清E2水平与其它各指标的相关性分析
大鼠血清E2水平与LEP、IL-6、sICAM-1、HCY、血清p-AP及脑脊液p-AP呈负相关(P<0.05)；与HDL呈正相关(P<0.05)。
5.雌激素治疗对脑缺血大鼠脑梗塞体积及Bcl-2表达的影响
与去卵巢局灶性脑缺血再灌注大鼠比较,雌激素治疗组大鼠其脑梗塞体积明显缩小,且Bcl-2表达水平显著增高(P<0.05)。结论：
1.急性脑梗塞患者血清E2水平较对照组显著降低,E2为脑梗塞患者的保护性因素；急性脑梗塞患者血清LEP、IL-6、sICAM-1、 HCY及脑脊液p-AP较对照组显著上升,LEP、IL-6、sICAM-1、HCY及脑脊液p-AP为脑梗塞患者的危险性因素；E2水平与脑梗塞多个危险因素密切相关,E2在一定程度上可反应脑梗塞病情程度及治疗反应情况。
2.雌激素治疗可有效缩小局灶性脑缺血再灌注大鼠脑梗塞体积,降低机体炎症反应、改善机体脂质及蛋白质代谢水平并发挥缺血脑保护作用,其机制可能与上调脑缺血再灌注后Bcl-2的表达有关,以上为临床脑梗塞的早期干预治疗奠定理论基础。
Objective
To determine the serum level of estrogen (E2), leptin (LEP), interleukin-6(IL-6), soluble intercellular adhesion molecule-1(sICAM-1), total cholesterol (TC), triglycerides (TG), high-density lipoprotein (HDL), low density lipoprotein Cholesterol (LDL) and homocysteine (HCY) in clinical patients with cerebral infarction and rats with focal cerebral ischemia-reperfusion injury; detect the level of amyloid protein (β-AP) in the serum and cerebrospinal fluid; detect some vascular related indicators including bilateral common carotid artery and the bilateral internal carotid artery peak flow velocity (PSV), bilateral carotid intima-film thickness (IMT) and the left and right carotid plaques crouse score in clinical patients with cerebral infarction; detect the level of Bel-2in local brain tissue of rats with focal cerebral ischemia-reperfusion injury. Analysis whether serum level of estrogen correlated to these indicators, then evaluate the protective effects of estrogen on brain infarction, and finally provide proof for early diagnosis and effective treatment of for clinical brain infarction patients.
Methods
Chose those acute cerebral infarction patients arrived in neurology within24hours after the onset of disease. Diagnosis wasconfirmed by craniocerebral CT and/or MRI, and it was also diagnosed according to the diagnostic criteria of the fourth national cerebrovascular disease conference. At the same time, some complications such as eliminate infectious diseases, autoimmune diseases, primary malignant tumor, and trauma were excluded. All patients with acute cerebral infarction were reviewed craniocerebral CT in2-3days after the admission, and the cerebral infarction volume were calculated by consult chef formula. Patients were grouped according to the needs of specific designs; a control group was conducted at the same time in the same period in the hospital patients. Rats with focal cerebral ischemia reperfusion (MCAO) were conducted as the animal model to study the protective effects of estrogen on acute cerebral infarction.
Serum levels of TC, TG, HDL and LDL in patients and rats were determined in a conventional method; the serum E2level was detected by radioimmunoassay; to detect Serum levels of LEP, IL-6and sICAM-1levels were detected by enzyme-linked immunosorbent (ELISA); plasma HCY levels were detected by Fluorescence polarization immunoassay (FPIA); levels ofβ-AP in serum and cerebrospinal fluid were detected by ELISA; expression of Bel-2protein was determined by immunohistochemical detection.
Results
1. Changes of serum E2and other index levels in clinical patients with cerebral infarction
(1) Compared with the control group, the E2levels decreased in the cerebral infarction group; the cerebral infarction volume and was negatively correlated with serum E2levels (P<0.05); serum E2levels in cerebral infarction patients are associated with diabetes, alcoholism, serum E2levels are lower in those diabetes and alcoholism patients than those without diabetes and alcoholism (P<0.05or P<0.01).
(2) Compared with the control group, the PSV, IMT and plaques crouse scores were significantly higher in the cerebral infarction group (P <0.05).
(3) Compared with the control group, the serum levels of LEP, il-6and sICAM1in the cerebral infarction group increased significantly (P<0.05or P<0.01). Among them, the serum levels of sICAM1and IL-6in the cerebral infarction group are closely related to the disease severity and the size of the lesions; serum levels of sICAM-1and IL-6in those patients under acute phase state is much far higher than those of remission (P<0.05or P<0.01); serum levels of sICAM-1and IL-6is far more higher in patients with large size lesion than those patients with small size lesion (P<0.05or P<0.01); In addition, serum levels of sICAM1in patients with cerebral infarction are associated with high blood pressure, diabetes, serum sICAM1levels are much higher in those patients with high blood pressure and diabetes than those without high blood pressure and diabetes (P<0.05or P<0.01).
(4) Compared with the control group, serum TC, TG and LDL levels in the cerebral infarction group increased significantly, while HDL levels decreased significantly (P<0.05or P<0.01).
(5) Compared with the control group, the serum HCY levels in the cerebral infarction group increased significantly (P<0.01); and there is gender differences in plasma HCY levels, plasma HCY levels in male patients was much higher than female patients (P<0.01).
(6) Compared with the control group, the serum β-AP levels reveled no obviously change in the cerebral infarction group (P>0.05); whileβ-AP levels in cerebrospinal fluid was significantly increased in the cerebral infarction group (P<0.05).
2. Correlation analysis of Serum levels of E2and other index levels in clinical patients with cerebral infarction
Serum levels of E2was negatively related to serum LEP, IL-6, sICAM-1TG, HCY and plaques crouse scores; serum levels of E21was positively correlated with the serum HDL; and negatively correlated with p-AP levels in cerebrospinal fluid (P<0.05or P<0.01).
3. Changes of serum E2and other index levels in rats (control group, MCAO group and estrogen treatment group)
Compared with the control group, serum levels of E2, TC, TG, LDL in rats of MCAO group revealed no obvious changes (P>0.05); serum levels of LEP, il-6, sICAM-1, HCY and obviously increased; while HDL levels significantly decreased; levels of β-AP in cerebrospinal fluid also significantly increased (P<0.05or P<0.01). Compared with the MACO group, serum levels of TC, TG, LDL in the estrogen therapy group revealed no obvious changes (P>0.05); serum levels of E2and HDL levels increased significantly; serum levels of LEP, il-6, sICAM-1, HCY andβ-AP significantly decreased; levels of β-AP in cerebrospinal fluid also significantly decreased (P<0.05or P<0.01).
4. Correlation analysis of Serum levels of E2and other index levels in rats
Serum levels of E2in rats was negatively related to serum LEP, il-6, sICAM-1, HCY, β-AP andβ-AP levels in cerebrospinal fluid (P<0.05); and were positively correlated with serum HDL (P<0.05).
5. The impact on infarction volume of estrogen therapy in rats with focal cerebral ischemia-reperfusion injury and its relation with Bcl-2expression
Compared to the MCAO group, the cerebral infarction volume significantly narrowed in rats of estrogen treatment group; and the expression of Bcl-2significantly increased (P<0.05).
Conclusions
1. Serum levels of E2in patients with acute cerebral infarction significantly decreased than control group and E2was a protective factor for patients with cerebral infarction; Serum levels of LEP, il-6, sICAM-1, HCY and β-AP levels in cerebrospinal fluid in patients with acute cerebral infarction significantly increased than control group and LEP, il-6, sICAM-1, HCY andβ-AP were risk factors for patients with cerebral infarction patients; E2levels were closely associated with multiple risk factors in patients with cerebral infarction, and to some extent E2could reflect the disease severity and response after certain treatment in patients with cerebral infarction.
2. Estrogen therapy could effectively narrow the infarction volume in rats after focal cerebral ischemia reperfusion injury, reduce the inflammatory reaction, improve body lipid and protein metabolism and regulate cell apoptosis, and then play an important role on neural protection in rats with cerebral infarction. Its mechanism may be related to that estrogen could increase the expression of Bel-2after cerebral ischemia reperfusion. This study provided some theoretical basis on estrogen intervention for clinical patients with cerebral infarction.
引文
[1]Petitti DB, Sideny S, Bernstein A, et al. Stroke in users of low-does oral contraceptiver [J]. N EngJ Med,1996,335 (1):8-12.
[2]Martin J. Kelly, Jian Qiu, et al. Rapid effects of estrogen on G protein-coupled receptor activation of potassium channels in the central nervous system (CNS) [J]. The Journal of Steroid Biochemistry and Molecular Biology,2002, 83(1-5):187-193.
[3]赵承军,孔斌,张炎,等.去势小鼠自体冷冻卵巢移植后海马神经元超微结构化[J].宁夏医科大学学报,2008,30(1)：4-6.
[4]Bi R, Broutman G, Foy MR, et al. The tyrosine kinase and mitogen-activated protein kinase pathways mediate multiple effects of estrogen in hippocampus [J]. Proc Natl Acad Sci USA,2000,97(7):3602-3607.
[5]Zwain IH, Yen SS, Cheng CY. Astrocytes cultured in vitro produce estradiol-17beta and express aromatase cytochrome P-450 (P-450 AROM) Mrna [J]. Biochim Biophys Acta,1997,1334(2-3):338-348.
[6]刘彬,谢俊霞.雌激素对多巴胺能神经元功能调节作用的研究进展[J].生理科学进展,2001,32(3)：259-261.
[7]王升,何瑞荣.雌激素心血管作用的研究进展[J].生理科学进展,2001,32(4)：337-339.
[8]张廷星,吴可贵,晋学庆,等.雌激素对自发性高血压大鼠心肾纤维化的影响[J].中国动脉硬化杂志,2003,11(3)：230-233.
[9]Dubal DB, Wise PM. Neuroprotective effects of estradiol in middle-aged female rats [J]. Endocrinology,2001,142(1):43-48.
[10]McCullough LD, Alkayed NJ, Traystmean RJ, et al. Postischemic estrogen reduces hypoperfusion and secondary ischemia after experimental stroke [J]. Stroke,2001,32(3):796-802.
[11]Green PS, Simpkins JW. Neuroprotective effects of estrogens:potential mechanisms of action [J]. Int J Dev Neurosci,2000,18(4-5):347-358.
[12]Dubal DB, Shughrue PJ, Wilson ME, et al. Estradiol modulates bcl-2 in cerebral ischemia:a potential role for estrogen receptors [J]. J Neurosci,1999,19:6385-6393.
[13]王春霞,包仕尧,刘春风,等.尼莫通和川芎嗪对脑缺血再灌注时c-fos和Bcl-2蛋白表达的影响[J].中国危重病急救医学,1999,11(10)：609-612.
[14]Alkayed NJ, Goto S, Sugo N, et al. Estrogen and Bcl-2:gene?induction and effect of transgene in experimental stroke [J]. J Neurosci,2001,21(19):7543-7550.
[15]Yu X, Rajala RV, M cGinnis JF, et al. Involvement of insulin/phosphoinositide 32kinase/Akt signal pathway in 17estradiol-mediated neuroprotection [J]. J Biol Chem,2004,279(13):13086-13094.
[16]Candelise L, Ciccone A. Gangliosides for acute ischaemic stroke [J]. Cochrane Database Syst Rev,2001, (4):94.
[17]Mingyue Liu, Melissa H, Kelley, et al. Neuroprotection of Sex Steroids [J]. Minerva Endocrinol,2010,35(2):127-143.
[18]Prentice RL, Manson JE, Langer RD, et al. Benefits and Risks of Postmenopausal Hormone Therapy When It Is Initiated Soon After Menopause [J]. Am J Epidemiol,2009,170(1):12-23.
[19]韩玲,张均.绝经后血浆激素水平与脑梗塞的关系[J].中国实用神经疾病杂志,2009,12(6)：33-34.
[20]Spence RD, Hamby ME, Umeda E, et al. Neuroprotection mediated through estrogen receptor-alpha in astrocytes [J]. Proc Natl Acad Sci USA.2011, 108(21):8867-8872.
[21]Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obsese gene and its human homologue [J]. Nature,1994,372(6505):425-432.
[22]Tartaglia LA. The leptin receptor Review [J]. Biol Chem,1997,272(10):6093-6096.
[23]Sahu A. Intracellular Leptin-Signaling Pathways in Hypothalamic Neurons:The Emerging Role of Phosphatidylinositol-3 Kinase-Phosphodiesterase-3B-cAMP Pathway [J]. Neuroendocrinology,2011,93:201-210.
[24]Mohsin Syed, Michael Cozart, Anessa C. et al. Ghrelin Restoration of Function In Vitro in Somatotropes from Male Mice Lacking the Janus Kinase (JAK)-Binding Site of the Leptin Receptor [J]. Endocrinology,2012,154(4): 1565-1576.
[25]Sinha MK. Human leptin, the hormone of adipose tissue [J]. Eur J Endocrinol, 1997,136(5):461-464.
[26]苏春芳,张颜华.瘦素与心血管疾病[J].山西医药杂志,2011,(48)：330-332.
[27]Bates, SH, Kulkarni RN, Seifert M, et al. Roles for leptin receptor/STAT3-dependent and-independent signals in the regulation of glucose homeostasis [J]. Cell Metabolism,2005,1(3):169-178.
[28]Balthasar N, Coppari R, McMinn J, et al. Leptin receptor signaling in POMC Neurons Is Required for Normal Body Weight Homeostasis [J]. Neuron.2004, 42(6):983-991.
[29]Ostiund RE, Yang JW, Klein S, et al. Relation between plasma leptin concentration and body fat, gender, diet, age and metabolic convariates [J]. J Clin Endocrinol Metab,1996,81(11):3909-3913.
[30]Saladin R, De Vos P, Guerre-Millo M, et al. Transient increase in obese gene expression after food intake or insulin administration [J]. Nature,1995, 377(6549):527-529.
[31]Leyva F, Godsland IF, Ghatei M, et al. Hyperleptine mia as a component of a metabolic sydrome of cardiovascular risk. Arcerioscler Thrombvascboil [J]. 1998,18(6):928-933.
[32]Soderberg S, Ahren B, Jansson JH, et al. Leptin is associated with increased risk of mycardial infraction [J]. J Infern Med,1999,246(4):409-418.
[33]Haynes WA, Morgan DA, Walsh SA, et al. Receptor mediated regional sympathetic nerve activation by leptin [J]. Clin Invest,1997,100(2):270-278.
[34]Fruhbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration [J]. Diabetes,1999,48(4):903-908.
[35]Quehenberger P, Exner M, Sunder PR, et al. Leptin induces endothelinl in endothelial cells in vitro [J]. Cire Res,2002,90(6):711-718.
[36]Park HY, Kwon HM, Lim HL, et al. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro [J]. Exp Mol Med,2001,33(2):95-102.
[37]Ribatti D, Nico B, Belloni AS, et al. Angiogenic activity in the chick embryo chofioallantoic membrane is in part mediated by endogenous fibroblast growth factor [J]. Int J Mol Med,2001,8(3):265-268.
[38]Yamagishi S, EdelStein D, Du X, et al. Leptin induces mitochondnial superoxide production and monoeyte chemoattractant protein-1 expression in aortic endothelial cells by increasing factory acid oxidation via protein kinase A [J]. J Biol Chim,2001,267(27):25096-25100.
[39]Nakata M, Yada T, Soejima N, et al. Leptin promotes aggregation of human platelets via the long form of its receptor [J]. Diabetes,1999,48(2):426-429.
[40]De Mitrio V, De Pergola G, Vettor R, et al. Plasma plasminogen activator inhibitorl is associated with plasma with lepin irrespetive of body ma88 index, body fat mauss and plasma insulian and metabolic parameters in premenopausal women [J]. Metabolism,1999,48(8):960-964.
[41]Kazumi T, Kawaguehi A, Katch J, et al. Fasting insulin and leptin serum levels are associatsd with systotic blood pressure independent of percentage body fat and body mass index [J]. Diabetes Care,1998,21(5):782-786.
[42]Mark AL, Shaffer RA, Corriea MLG, et al. Contrasting blood pressure effects of obesity in leptin deficient ob/ob mice and agouti yellow obese mice [J]. J Hypertens,1999,17(10):1949-1953.
[43]Haynes WG, Sivutz WI, Morgan DA, et al. Sympathetic and cardiorenal actions of leptin [J]. Hypertension,1997,30(3):619-623.
[44]Kimura K, Tsuda K, Baba A, et al. Involvement of nitric oxide in endothelium-dependent arterial relaxation by leptin [J]. Biochem Biophys Res Commun,2000,273(1):745-749.
[45]Kuo JJ, Jones OB, Hall JE. Inhibition of NO synthesis enhances ohronic car-diovascular and renal actions of leptin [J]. Hypertension,2001, 37(2):670-676.
[46]Adamczak M, Kokot F, Wiecek AW. Relationship between plasma reni n profile and leptinaemia in patients with essential hypertension [J]. J Hum Hypertens,2000,14(8):503-509.
[47]Shimamoto K. Insulin resistance syndrome and hypertension [J]. Hokkaido Loaku Zasshi,2000,75(1):9-14.
[48]Cases JA, Gabriely I, Ma XH, et al. Physiological increase in Dlasma leptin markedly inhibits insulin secretion in vivo [J]. Diabetes,2001,50(2):348-352.
[49]Makris TK, Stavroulakis GA, Krespi PG, et al. Elevated plasma immunoreaetive leptin levels preexist in healthy offspring of patients with essential hypertension [J]. Am Heart J,1999,138(5Pt1):922-925.
[50]Anim-Nyame N, Sooranne SR, Steer PJ, et al. Longitudinal analysis of maternal plasma leptin concentrations during normal pregnancy and preeelampsia [J]. Hum Repord,2000,15(9):2033-2036.
[51]Mise H, Savaga N, Matsumoto T, et al. Augment placental production of leptin in preeclampsia possible involvement of placental hypoxia [J]. J Clin Endocrinal Metab,1998,83(9):3225-3229.
[52]Ianderson JG, Patterson CC, Hadden OR. leptin concentrations in the umbilical vein and relationship to maternal and to maternal and arthropometry [J]. J Record Med,2002,47(8):645-650.
[53]Chen H, Charlat O, Tartaglia LA, et al. Evidence that the diabetes gene encodes the leptin receptor in the abult rat gene in db/db mice [J]. Cell,1996, 84(3):491-495.
[54]朱宪彝.临床内分泌学[M].天津：天津科学技术出版社,1993,421.
[55]汪启迪.瘦素与其他相关激素间的互调作用[J].国外医学.内分泌学分册,1999,19(5)：196.
[56]Stefan S, Bo A, Birgitta S, et al. Teptin is a risk maker for first-ever hermorrhagic Stroke in a population-based cohort [J]. Stroke,1999, 30(2):328-337.
[57]何静,袁秀珠,尹宁,等.脑卒中急性期患者血清leptin水平及其相关性研究[J].卒中与神经疾病,2003,10(5)：301-304.
[58]Lindenstrom E, Boysen G, Nyboe J. Influence of total cholesterol, hight density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease:the Copenhagen city heart study [J]. BMJ,1994,309(6946):11-15.
[59]Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay:a central control of bone mass [J]. Cell,2000, 100(2):197-207.
[60]Maor G, Rochwerger M, Segev Y, et al. Leptin acts as a growth factor on the chondrocytes of skeletal growth centers [J]. Bone Miner Res,2002, 17(6):1034-1043.
[61]Sato M, Takeda N, Sarui H, et al. Association between serum leptin concentrations and bone mineral density, and biochemical markers of bone turnover in adult men [J]. Clin Endocrinol Metab,2001,86(11):5273-5276.
[62]Karnafel W. Diabetic cardiomyopathy. Pathophysiology and clinical implications [J]. Przegl Lek,2000,57(4):9-11.
[63]Unger RH, Zhou YT, Qrci L. Regulation of fatty acid homeostasis in cells: novel role of leptin [J]. Proc Natl Acad Sci USA,1999,96(5):2327-2332.
[64]Unger RH. Weapons of lean body mass destruction:the role of ectopic lipids in the metabolic syndrome [J]. Endocrinology,2003,144(12):5159-5165.
[65]Duprez DA, Debuyzere MI, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients [J].Eur Heart J,1998,19(9):1371-1376.
[66]Brilla CG, Matsubara LS, Weber KT. Antifibrotic effect of spironolactone in preventingmyocardial fibrosis in systemetic arterial hypertension [J]. Am J Cardiol,1993,71(1):12-16.
[67]Sato A, Suzuki Y, Shibata H. Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients [J]. Hypertens Res,2000,23(1):25-31.
[68]Vogel G. Leptin:a trigger for puberty [J]. Science,1996,274(5292):1466-1467.
[69]Carcia Mayor RV, An drade MA, Rios M, et al. Serum leptin levels in normal children:relationship to age, gender, body mass index, pituitarygonadal hormones and pubertal stage [J]. Clin Endocrinol Metab,1997,82(9):849-855.
[70]孙长颢,于春媛,王舒然,等.儿童瘦素水平对青春发育的作用[J].中华预防医学杂志,2001,35(5)：293-296.
[71]Yu WH, Kimura M, Walezewska A, et al. Role of leptin in hypothalamic-pituitary functionJ [J]. Proc Natc Acad,1997,94(3):1023-1028.
[72]Wang Q, Santizo R, Baughman VL, et al. Estrogen provides neuroprotection in transient forebrain ischemia through perfusion-independent mechanisms in rats [J]. Stroke,1999,30:630-637.
[73]Alkayed NJ, Harukuni I, Kimes AS, et al. Gender-linked brain injury in experimental stroke [J]. Stroke,1998,29:159-165.
[74]Rusa R, Alkayed NJ, Crain BJ, et, al.17β-estradiol reduces stroke injury in estrogen-deficient female animals [J]. Stroke,1999,30:1665-1670.
[75]Green PS, Gridley KE, Simpkins JW. Nuclear estrogen receptor-independent neuroprotection by estratrienes:a novel interaction with glutathione [J]. Neuroscience,1998,84:7-10.
[76]Weaver CE, Park-Chung M, Gibbs TT, et al.17β-estradiol protects against NMDA-induced excitotoxicity by direct inhibition of NMDA receptors [J]. Brain Res,1997,761:338-341.
[77]Dubal DB, Shughrue PJ, Wilson ME, et al. Estradiol modulates bcl-2 in cerebral ischemia:a potential role for estrogen receptors [J]. J Neurosci,1999, 19:6385-6393.
[78]Mattson MP, Robinson N, Guo Q. Estrogens stabilize mitochondrial function and protect neural cells against the pro-apoptotic action of mutant presenilin-1 [J]. Neuroreport,1997,8:3817-3821.
[79]Behl C, Skutella T, Lezoualch F, et al. Neuroprotection against oxidative stress by estrogens:structure-activity relationship [J]. Mol Pharmacol,1997,51:535-541.
[80]Ayres S, Abplanalp W, Liu JH, et al. Mechanisms involved in the protective effect of estrodiol-17 beta on lipid peroxidation and DNA damage [J]. Am J Physiol,1998,274:1002-1008
[81]White RE, Darkow DJ, Lang JL. Estrogen relaxes coronary arteries by opening BK Ca channels through a cGMP-dependent mechanism [J]. Circ Res,1995, 77:936-942..
[82]Palmon SC, Williams MJ, Littleton-Kearney MT, et al. Estrogen increases cGMP in selected brain regions and in cerebral micro vessels [J]. J Cereb Blood Flow Metab,1998,18:1248-1252.
[83]McNeill AM, Kim N, Duckles SP, et al. Chronic estrogen treatment increases levels of endothelial nitric oxide synthase protein in rat cerebral microvessels [J]. Stroke,1999,30:2186-2190.
[84]Shi J, Panickar KS, Yang SH, et al. Estrogen attenuates over-expression of beta-amyloid precursor protein messager RNA in an animal model of focal ischemia [J]. Brain Res,1998,810:87-92
[85]Green PS, Gridley KE, Simpkins JW. Estradiol protects against beta-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells [J]. Neurosci Lett,1996,218:165-168.
[86]Honjo H, Tanaka K, Kashiwagi T, et al. Senile dementia-Alzheimer's type and estrogen [J]. Horm Metab Res,1995,27:204-207.
[87]Yaffe K, Sawaya G, Lieberburg I, et al. Estrogen therapy in postmenopausal women:effects on cognitive function and dementia [J]. JAMA,1998,279: 688-695.
[88]Berman KF, Schmidt PJ, Rubinow DR, et al. Modulation of cognition-specific cortical activity by gonadal steroids:a positron-emission tomography study in women [J]. Proc Natl Acad Sci USA,1997,94:8836-8841.
[89]Westendorp ICD, Veld BAI, Bots ML, et al. Hormone replacement therapy and intima-media thickness of the common carotid artery:the rotterdam study [J]. Stroke,1999,30:2561-2567.
[90]Petitti DB, Sidney S, Quesenberry CP Jr, et al. Ischemic stroke and use of estrogen and estrogen/progestogen as hormone replacement therapy [J]. Stroke, 1998,29:23-28.
[91]Houseknecht KL, Baile C A, Matteri R L, et al. The biology of leptin:a review [J]. Anim Sci,1998,76:1405-1420.
[92]Loffeda S, Yang S Q, Lin H Z, et al. Leptin regulates proinflammatory immune responses [J]. FASEB 1998,12(1):57-65.
[93]张丽.瘦素与脂肪肝[J].国外医学内分泌学分册,2004,24(1)：65-67.
[94]郑善德.瘦素与糖尿病动脉粥样硬化[J].国外医学内分泌学分册,2003,23(5)：322-324.
[95]Dicou E, Attoub S, Gressens P. Neuroprotective effects of leptin in vivo and in vitro [J].Neuvoreport.2001,12 (18):3947-3951.
[96]Soderberg S, Ahren B, Stegmayr B, et al. Leptin is risk marker for first-ever hemorrhagic stroke in a population-gased cohort [J]. Strok 1999,30 (2):328-337.
[97]金嘉林,田成功.瘦素的作用与瘦素抵抗[J].国外医学内分泌学分册,2002,22(2)：54-56.
[98]Biffl WL, Moore EE, Moore FA, et al. IL-6 in the injured patient marker of injury or mediator of inflammation [J]. Ann Surg,1996,224(5):647-664.
[99]Mckenting EG, Andrews PJD. Cytokines and adhesion molecules in acute brain injury [J]. Br J Anaesth,1998,80(1):77-84.
[100]Martin-Ancel A, Garcia-Alix A, Pascal Scalcedo D, et al. Interleukin-6 inthe cerebrospinal fluid after perinatal asphyxia is related to early and late neurological manifestations [J]. Pediatrics,1997,100(5):789-794.
[101]Campel IL, Ahraham CR, Mesliah E. Neurological diseases involved in transgenic mice by cerebral overpression of IL-6 [J]. Proc Natl Acad Sci USA, 1993,90(21):10061-10065.
[102]Rothlein R, Mainolfi EA, Czajkowski M, et al. A form of circulating ICAM-1 in human serum [J]. J Immunol,1991,147(11):3788-3793.
[103]Okada Y, Copeland BR, Mori E, et al. P-selec and intercellular adhesion molecular-1 expression after focal brain ischemia and reperfusion [J]. Stroke, 1994,25:202-221
[104]Ge H, Wen Y, Yang G, et al. Increased expression of intercellular adhesion molecule-1 in focal cerebral ischemia model [J]. chin Med J(Engl),2000, 113:75-79
[105]Vemuganti R, Dempsey RJ, Bowen KK. Inhibition of intercellular molecule-1 protein expression by antisense oligonucleotides is five after transient middle cerebral occlusion in rat [J]. Stroke,2004,35:179-184
[106]Shyu KG, Chang H, Lin CC, et al. Serum level of intercellular adhesion molecule-1 in patients with acute ischemia stroke [J]. J Neurol,1997, 244(2):90-93.
[107]Bitsch A, klene W, Murtada L, et al. A longitudinal prospective study of soluble adhesion molecules in acute stroke [J]. Stroke,1998,29(10):2129-2135.
[108]Matsuda S, Went C, Morita F, et al. Interleukin-6 prevents ischemia-induced learning disability and neuronal and synaptic loss in gerbils [J]. Neurosci lett, 1996,204, (1-2):109-112.
[109]Shibata M, Ueshima K, Harada M, et al. Effect of magnesium sulfate pretreatment and significance of matrix metalloproteinase-1 and interleukin-6 levels in coronary reperfusion therapy for patients with acute myocardial infarction [J]. Angiology,1999,50(7):573-582.
[110]Rosenberg GA, estrada EY. Dencoft JE. Matrix metaltoproteinase and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain [J]. Stroke,1998,29(10):2189-2195.
[111]Luheshi GN, Stefferl A, Turnbull AV, et al. Febrile response to tissue inflammation involves both peripheral and briar il-1 and TNF-alpha in the rat [J]. Am J Physiol,1997,272(3):862-868
[112]肖岚,黎杏群.白介素-6与脑缺血损伤[J].国外医学神经病学神经外科学分册,2000,27：258-261.
[113]Clark WM, Rinker LG, Lessov NS, et al. Time course of IL-6 Expression in experimental CNS ischemia [J]. Neurol Res,1999,1 (3):287-292.
[114]Anderson BO, Moore EE, Banerjee A. Phospholipase A2 regulates Critical inflammatory mediators of multiple organ failure [J]. J Surg Res,1994, 56(2):199-205.
[115]Ballou LR, Laulederkind SJ, Rosloniec EF, et al. Ceramide signaling andthe immune response [J]. Biochim Biophys Acta,1996,1301(3):273-287.
[116]Ishihara K, Hirano T. Molecular basis of the cells pecificity of cytokine action [J]. Biochim Biophys Acta,2002,1592(3):281-296.
[117]Ueland PM, Refsum H, Stabler SP, et al. Total homocysteine in plasma or serum:methods and clinical applications [J]. Clin Chem,1993,39:1764-1779.
[118]Macy PA, Homocysteine:predictor of thrombotic disease [J]. Clin Lab Sci. 2001,14(4):272-275.
[119]Obaidi AL, Stubbs P, Amersey R, et al. Acute and onvalescent changes in plasma homocysteine concentrations in acute coronary syndromes [J]. Heart, 2001,85(4):380-384.
[120]Markus HS, Ali N, Swaminathan R, et al. A common polymorphism in the methylen-etetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease [J]. Stroke,1997,28:1739-1743.
[121]Delport R, Ubbink JB, Vermaak WJ, et al. Hyperhomocysteinaemia in black patients with cerebral thrombosis [J]. QJM,1997,90:635-639.
[122]Ray JG, Harvey DT. Hyperhomocysteinemia as a cause of premature stroke in a young patient [J]. Arch Phys Med Rehabil,1998,79:343-345.
[123]Penix LP. Ischemic strokes secondary to vitamin B12 deficiency-induced hyper-homo-cystinemia [J]. Neurology,1998,51:622-624.
[124]Candito M, Bedoucha P, Mahagne MH, et al. Total plasma homocysteinedetermination by liquid chromatography before and after methionine loading. Results in cerebrovascular disease [J]. Chromatogr B Biomed Sci Appl,1997,692:213-216.
[125]Evers S, Koch&nbs P, Grotemeyer KH, et al. Features, symptoms, and neurophysiological findings in stroke associated with hyperho-mocysteinemia [J]. Arch Neurol,1997,54:1276-1282.
[126]Vila N, Deulofeu R, Chamorro A, et al. Plasma homocysteine levels in patients with ischemic cerebral infarction [J]. Med Clin (Barc),1998,110:605-608.
[127]Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effect of homocysteine are modulated by endothelium-derived relaxing factor and relatedoxides of nitrogen [J]. J Clin Invest,1993,91:308-318.
[128]Rodgers GM, Conn MT. Homocysteine. an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells [J]. Blood,1990, 75:895-901.
[129]Franken DG, Boers GH, Blom HJ, et al. Treatment of mild hyperhomcysteinemia in vascular disease patients [J]. Arterioscler Thromb, 1994,14:465-470.
[130]Franken DG, Boers GH, Blom HJ, et al. Treatment of mild hyperhomcysteinemia in vascular disease patients [J]. Arterioscler Thromb, 1994,14:465-470.
[131]Glueck CJ, Shaw P, Lang JE, et al. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients [J]. Am J Cardiol,1995,75:132-136.
[132][] Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis [J]. Thromb Haemost,1999,81:165-176.
[133]Lalouschek W, Aull S, Serles W, et al. Genetic and nongenetic factors influencing plasma homocysteine levels in patients with ischemic cerebrovascular disease and healthy control subjects [J]. J Lab Clin Med,1999, 133:575-582.
[134]Boysen G, Brander T, Christensen H, et al. Homocysteine and risk of recurrent stroke [J]. Stroke,2003,34:1258-1261.
[135]Martinelli I, Battaglioli T, Pedotti P, et al. Hyperhomocysteine in cerebral vein thrombosis [J]. Blood,2003,102:1363-1366.
[136]McCully KS. Vascular pathology of homocysteine:implicat ions of the pathogenesis of arteiosclerosis [J]. Am J Pathol,1969,56(1):111-128.
[137]Perry IJ, Refsum H, Morris RW, et al, Prospective study of serum homocysteine concentration and risk of stroke in middle aged British men [J].Lancet,1995, 346(8987):1395-1398.
[138]Gao W, Tang J. Hyperhomocysteinemia:a new risk factor for many kinds of diseases:summary for national symposium on hyperhomocys teinemia and disease [J]. China Med J,1999,79(1):15-19.
[139]Rhoads GG, Dahlen G, Berg K, et al. LP(a) Lipoprotein as a risk factor f or myocardial infarction [J]. JAMA,1986,256:2540-2544.
[140]Durrington P N, Ishola M, Hunt L, et al. Apolipoprotein(a), Al, and B and p arental history in men with early onset ischemic heart disease [J]. Lancet,1988, 1:1070-1073.
[141]Hoefler G, Harnoncourt F, Paschke E, et al. Lipoprotein (a) a risk for myocardial infarction [J]. Arteriosclerosis,1988,8:398-401.
[142]Grenest J Jr, Jenner J L, McNamara J R, et al. Prevalence of lipoprotein(a) excess in coronary artery disease [J]. Am J Cardiol,1991,67:1039-1045.
[143]Murai A, Miyahara T, Fujimoto N, et al. Lipoprotein(a) as a risk factor for coronary heart disease and cerebral infarction [J]. Arterioscleros is,1986, 59:199-204.
[144]Jurgans G, Taddeipeters WC, Koeltringer P, et al. Lipoprote in(a) serum concentration and apolipoprotein(a) phenotype correlate with severit y andpresence of ischemic cerebrovascular disease [J]. Stroke,1995, 26:1841-1848.
[145]Suet Y, Thomas HKN, Siu TY, et al. Pattern of cerebral arterioscleros isin Hong Kong Chinese:severity in intracranial and extracranial vessels [J]. Stroke,1993, 24:779-784.
[146]刘芳玲,张葆樽,田玉旺,等.脑卒中患者颅内外动脉形态变化分析[J].中华医学杂志,1996,76：832-835.
[147]Glenner GG, Wong CW. Alzheimer's disease:initial report of the purification and characterization of a novel cerebrovascular amyloid protein [J]. Biochem Biophys Res Commun,1984,120:885-90
[148]Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD) Part Ⅱ Standardization of the neuropathologic assessment of Alzheimer's disease [J]. Neurology,1991, 41(4):479-486.
[149]Gandy S. Oxygen radical metabolism in vivo:molecular genetic models and assays [J].Neurobiology of Aging,1994,15(4):471-482.
[150]Wisniewski HM Beta protein fibrillogenesis and its impact on neuropil and microvessels [J]. Neurobiology of Aging,1993,14(6):665-666.
[151]Nakaumra T, Shoji M, Harigaya Y, et alβ-Amyloid protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease [J]. Ann Neurol,1994,36(6):903-911.
[152]Van Gool WA, Schenk DB, Bolhuis PA. Concentrations of β-Amyloid protein in cerebrospinal fluid increase with age in patients free from neurodegeneration disease [J].Neurosci lett,1994,172(3):122124.
[153]Pirttila P, Kim KS, Mehta PD, et al. Soluble amyloid β-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementiaand controls [J]. Neurol Sci,1994,127(7):90-95.
[154]Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of p-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease [J]. Ann Neurol,1995,38(4):643-648.
[155]Nitsh RM, Rebeck W, Deng M, et al. Cerebrospinal fluid levels of amyloid protein in Alzheimer's disease:Inverse correlation with severity of dementia and effect of Apolipoprotein E genotype [J]. Ann Neurol,1995,37(4):512-518.
[156]Crawford F, Suo Z, Fang C, et al.Characteristics of the in vitro uasoactivlty of beta-amgloid peptides[J].Exp Neurol,1998,150 (1):159-168.
[157]王爱民,周莹,肖波,等.脑梗塞患者血清高敏C反应蛋白水平的变化及其临床意义[J].临床神经病学杂志,2005,18(2)：153-154.
[158]华洁,牛国忠,李保华.急性脑血管疾病患者血清C反应蛋白测定的临床意义[J].中华急诊医学杂志,2003,12(7)：483-484.
[159]Adams JM, Cory S. The Bcl-2 protein family:arbiters of cell survival [J].Science,1998,281(5381):1322-1326.
[160]Youle RJ, Strasser A. The BCL-2 protein family:opposing activities that mediate cell death [J]. Nature Reviews Molecular Cell Biology,2008, 9(1):47-59.
[161]Alkayed NJ, Murphy SJ, Traystman RJ, et al. Neuroprotective effects of female gonadal steroids in reproductively senescent female rats [J]. Stroke,2000,31 (1):161-168.
[162]Andrea Cardona-Rossinyol, Margalida Mir, Victor Caraballo-Miralles, et al. Neuroprotective Effects of Estradiol on Motoneurons in a Model of Rat Spinal Cord Embryonic Explants [J]. Cellular and Molecular Neurobiology,2013, 33(3):421-432.
[163]Merchenthaler L, Dellovade TL, Shughrue PJ. Neuroprotection by Estrogen in Animal Models of Global and Focal ischemia [J]. Annals of the New York Academy of Sciences,2003,1007:89-100.
[164]Zhao H, Yenari MA, Cheng D, et al. Bcl-2 overexpression protects against neuron loss within the ischemic margin following experimental stroke and inhibits cytochrome c translocation and caspase-3 activity [J]. Journal of Neurochemistry,2003,85(4):1026-1036.
[165]Prakasa Babu P, Yoshida Y, Su M, et al. Immunohistochemical expressionof Bcl-2, bax and cytochrome c following focal cerebral ischemia and effect of hypothermia in rat [J]. Neuroscience Letters,2000,291(3):196-200.
[166]Roof RL, Hall ED. Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone [J]. J Neurotrauma,2000, 17(5):367-3881.
[167]Moscal L, Banka CL, Benjamin EJ. et al. Evidence-based guidelines for cardiovascular disease prevention in women 2007 [J]. Circulation,2007, 49(11):1230-1250.
[168]Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke:2002 Update [J]. Circulation, 2002,1069(3):388-391.
[169]Blaustein JD, Cytoplasmic estrogen receptors in rat brain:immunocytochemical evidence using three antibodies with distinct epitopes [J]. Endocrinology,1992, 131:1336-1342
[170]Liu R, Yang SH. Window of opportunity:Estrogen as a treatment for ischemic stroke [J]. Brain Res,2013,8993(13):76-80.
[171]Simpkins JW, Rajakumar G, Zhang YQ, et al. Estrogens may reduce mortality and ischemic damage caused by middle cerebral arteryocclusion in the female rat [J]. Neurosurg,1997,87:724-730.
[172]Toung TJ, Traystman RJ, Hum PD. Estrogen mediated neuroprotection after experimental stroke in male rats [J]. Stroke,1998,29(8):1666-1670.
[173]Nakamura T, Xi G, Keep RF, et al. Effects of endogenous and exogenous estrogen on intracerebral hemorrhage-induced brain damage in rats [J]. Acta Neurochir Suppl,2006,96:218-221
[174]Nelson HD, Walker M, Zakher B, et al. Menopausal hormone therapy for the primary prevention of chronic conditions:a systematic review to update the U.S. Preventive Services Task Force recommendations [J]. Ann Intern Med,2012, 157:104-113.
[175]Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement the-rapy on cardiovascular events in recently postmenopausal women: randomised trial [J]. BMJ,2012,345:6409.
[2]Martin J. Kelly, Jian Qiu, et al. Rapid effects of estrogen on G protein-coupled receptor activation of potassium channels in the central nervous system (CNS) [J]. The Journal of Steroid Biochemistry and Molecular Biology,2002, 83(1-5):187-193.
[3]赵承军,孔斌,张炎,等.去势小鼠自体冷冻卵巢移植后海马神经元超微结构化[J].宁夏医科大学学报,2008,30(1)：4-6.
[4]Bi R, Broutman G, Foy MR, et al. The tyrosine kinase and mitogen-activated protein kinase pathways mediate multiple effects of estrogen in hippocampus [J]. Proc Natl Acad Sci USA,2000,97(7):3602-3607.
[5]Zwain IH, Yen SS, Cheng CY. Astrocytes cultured in vitro produce estradiol-17beta and express aromatase cytochrome P-450 (P-450 AROM) Mrna [J]. Biochim Biophys Acta,1997,1334(2-3):338-348.
[6]刘彬,谢俊霞.雌激素对多巴胺能神经元功能调节作用的研究进展[J].生理科学进展,2001,32(3)：259-261.
[7]王升,何瑞荣.雌激素心血管作用的研究进展[J].生理科学进展,2001,32(4)：337-339.
[8]张廷星,吴可贵,晋学庆,等.雌激素对自发性高血压大鼠心肾纤维化的影响[J].中国动脉硬化杂志,2003,11(3)：230-233.
[9]Dubal DB, Wise PM. Neuroprotective effects of estradiol in middle-aged female rats [J]. Endocrinology,2001,142(1):43-48.
[10]McCullough LD, Alkayed NJ, Traystmean RJ, et al. Postischemic estrogen reduces hypoperfusion and secondary ischemia after experimental stroke [J]. Stroke,2001,32(3):796-802.
[11]Green PS, Simpkins JW. Neuroprotective effects of estrogens:potential mechanisms of action [J]. Int J Dev Neurosci,2000,18(4-5):347-358.
[12]Dubal DB, Shughrue PJ, Wilson ME, et al. Estradiol modulates bcl-2 in cerebral ischemia:a potential role for estrogen receptors [J]. J Neurosci,1999,19:6385-6393.
[13]王春霞,包仕尧,刘春风,等.尼莫通和川芎嗪对脑缺血再灌注时c-fos和Bcl-2蛋白表达的影响[J].中国危重病急救医学,1999,11(10)：609-612.
[14]Alkayed NJ, Goto S, Sugo N, et al. Estrogen and Bcl-2:gene?induction and effect of transgene in experimental stroke [J]. J Neurosci,2001,21(19):7543-7550.
[15]Yu X, Rajala RV, M cGinnis JF, et al. Involvement of insulin/phosphoinositide 32kinase/Akt signal pathway in 17estradiol-mediated neuroprotection [J]. J Biol Chem,2004,279(13):13086-13094.
[16]Candelise L, Ciccone A. Gangliosides for acute ischaemic stroke [J]. Cochrane Database Syst Rev,2001, (4):94.
[17]Mingyue Liu, Melissa H, Kelley, et al. Neuroprotection of Sex Steroids [J]. Minerva Endocrinol,2010,35(2):127-143.
[18]Prentice RL, Manson JE, Langer RD, et al. Benefits and Risks of Postmenopausal Hormone Therapy When It Is Initiated Soon After Menopause [J]. Am J Epidemiol,2009,170(1):12-23.
[19]韩玲,张均.绝经后血浆激素水平与脑梗塞的关系[J].中国实用神经疾病杂志,2009,12(6)：33-34.
[20]Spence RD, Hamby ME, Umeda E, et al. Neuroprotection mediated through estrogen receptor-alpha in astrocytes [J]. Proc Natl Acad Sci USA.2011, 108(21):8867-8872.
[21]Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obsese gene and its human homologue [J]. Nature,1994,372(6505):425-432.
[22]Tartaglia LA. The leptin receptor Review [J]. Biol Chem,1997,272(10):6093-6096.
[23]Sahu A. Intracellular Leptin-Signaling Pathways in Hypothalamic Neurons:The Emerging Role of Phosphatidylinositol-3 Kinase-Phosphodiesterase-3B-cAMP Pathway [J]. Neuroendocrinology,2011,93:201-210.
[24]Mohsin Syed, Michael Cozart, Anessa C. et al. Ghrelin Restoration of Function In Vitro in Somatotropes from Male Mice Lacking the Janus Kinase (JAK)-Binding Site of the Leptin Receptor [J]. Endocrinology,2012,154(4): 1565-1576.
[25]Sinha MK. Human leptin, the hormone of adipose tissue [J]. Eur J Endocrinol, 1997,136(5):461-464.
[26]苏春芳,张颜华.瘦素与心血管疾病[J].山西医药杂志,2011,(48)：330-332.
[27]Bates, SH, Kulkarni RN, Seifert M, et al. Roles for leptin receptor/STAT3-dependent and-independent signals in the regulation of glucose homeostasis [J]. Cell Metabolism,2005,1(3):169-178.
[28]Balthasar N, Coppari R, McMinn J, et al. Leptin receptor signaling in POMC Neurons Is Required for Normal Body Weight Homeostasis [J]. Neuron.2004, 42(6):983-991.
[29]Ostiund RE, Yang JW, Klein S, et al. Relation between plasma leptin concentration and body fat, gender, diet, age and metabolic convariates [J]. J Clin Endocrinol Metab,1996,81(11):3909-3913.
[30]Saladin R, De Vos P, Guerre-Millo M, et al. Transient increase in obese gene expression after food intake or insulin administration [J]. Nature,1995, 377(6549):527-529.
[31]Leyva F, Godsland IF, Ghatei M, et al. Hyperleptine mia as a component of a metabolic sydrome of cardiovascular risk. Arcerioscler Thrombvascboil [J]. 1998,18(6):928-933.
[32]Soderberg S, Ahren B, Jansson JH, et al. Leptin is associated with increased risk of mycardial infraction [J]. J Infern Med,1999,246(4):409-418.
[33]Haynes WA, Morgan DA, Walsh SA, et al. Receptor mediated regional sympathetic nerve activation by leptin [J]. Clin Invest,1997,100(2):270-278.
[34]Fruhbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration [J]. Diabetes,1999,48(4):903-908.
[35]Quehenberger P, Exner M, Sunder PR, et al. Leptin induces endothelinl in endothelial cells in vitro [J]. Cire Res,2002,90(6):711-718.
[36]Park HY, Kwon HM, Lim HL, et al. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro [J]. Exp Mol Med,2001,33(2):95-102.
[37]Ribatti D, Nico B, Belloni AS, et al. Angiogenic activity in the chick embryo chofioallantoic membrane is in part mediated by endogenous fibroblast growth factor [J]. Int J Mol Med,2001,8(3):265-268.
[38]Yamagishi S, EdelStein D, Du X, et al. Leptin induces mitochondnial superoxide production and monoeyte chemoattractant protein-1 expression in aortic endothelial cells by increasing factory acid oxidation via protein kinase A [J]. J Biol Chim,2001,267(27):25096-25100.
[39]Nakata M, Yada T, Soejima N, et al. Leptin promotes aggregation of human platelets via the long form of its receptor [J]. Diabetes,1999,48(2):426-429.
[40]De Mitrio V, De Pergola G, Vettor R, et al. Plasma plasminogen activator inhibitorl is associated with plasma with lepin irrespetive of body ma88 index, body fat mauss and plasma insulian and metabolic parameters in premenopausal women [J]. Metabolism,1999,48(8):960-964.
[41]Kazumi T, Kawaguehi A, Katch J, et al. Fasting insulin and leptin serum levels are associatsd with systotic blood pressure independent of percentage body fat and body mass index [J]. Diabetes Care,1998,21(5):782-786.
[42]Mark AL, Shaffer RA, Corriea MLG, et al. Contrasting blood pressure effects of obesity in leptin deficient ob/ob mice and agouti yellow obese mice [J]. J Hypertens,1999,17(10):1949-1953.
[43]Haynes WG, Sivutz WI, Morgan DA, et al. Sympathetic and cardiorenal actions of leptin [J]. Hypertension,1997,30(3):619-623.
[44]Kimura K, Tsuda K, Baba A, et al. Involvement of nitric oxide in endothelium-dependent arterial relaxation by leptin [J]. Biochem Biophys Res Commun,2000,273(1):745-749.
[45]Kuo JJ, Jones OB, Hall JE. Inhibition of NO synthesis enhances ohronic car-diovascular and renal actions of leptin [J]. Hypertension,2001, 37(2):670-676.
[46]Adamczak M, Kokot F, Wiecek AW. Relationship between plasma reni n profile and leptinaemia in patients with essential hypertension [J]. J Hum Hypertens,2000,14(8):503-509.
[47]Shimamoto K. Insulin resistance syndrome and hypertension [J]. Hokkaido Loaku Zasshi,2000,75(1):9-14.
[48]Cases JA, Gabriely I, Ma XH, et al. Physiological increase in Dlasma leptin markedly inhibits insulin secretion in vivo [J]. Diabetes,2001,50(2):348-352.
[49]Makris TK, Stavroulakis GA, Krespi PG, et al. Elevated plasma immunoreaetive leptin levels preexist in healthy offspring of patients with essential hypertension [J]. Am Heart J,1999,138(5Pt1):922-925.
[50]Anim-Nyame N, Sooranne SR, Steer PJ, et al. Longitudinal analysis of maternal plasma leptin concentrations during normal pregnancy and preeelampsia [J]. Hum Repord,2000,15(9):2033-2036.
[51]Mise H, Savaga N, Matsumoto T, et al. Augment placental production of leptin in preeclampsia possible involvement of placental hypoxia [J]. J Clin Endocrinal Metab,1998,83(9):3225-3229.
[52]Ianderson JG, Patterson CC, Hadden OR. leptin concentrations in the umbilical vein and relationship to maternal and to maternal and arthropometry [J]. J Record Med,2002,47(8):645-650.
[53]Chen H, Charlat O, Tartaglia LA, et al. Evidence that the diabetes gene encodes the leptin receptor in the abult rat gene in db/db mice [J]. Cell,1996, 84(3):491-495.
[54]朱宪彝.临床内分泌学[M].天津：天津科学技术出版社,1993,421.
[55]汪启迪.瘦素与其他相关激素间的互调作用[J].国外医学.内分泌学分册,1999,19(5)：196.
[56]Stefan S, Bo A, Birgitta S, et al. Teptin is a risk maker for first-ever hermorrhagic Stroke in a population-based cohort [J]. Stroke,1999, 30(2):328-337.
[57]何静,袁秀珠,尹宁,等.脑卒中急性期患者血清leptin水平及其相关性研究[J].卒中与神经疾病,2003,10(5)：301-304.
[58]Lindenstrom E, Boysen G, Nyboe J. Influence of total cholesterol, hight density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease:the Copenhagen city heart study [J]. BMJ,1994,309(6946):11-15.
[59]Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay:a central control of bone mass [J]. Cell,2000, 100(2):197-207.
[60]Maor G, Rochwerger M, Segev Y, et al. Leptin acts as a growth factor on the chondrocytes of skeletal growth centers [J]. Bone Miner Res,2002, 17(6):1034-1043.
[61]Sato M, Takeda N, Sarui H, et al. Association between serum leptin concentrations and bone mineral density, and biochemical markers of bone turnover in adult men [J]. Clin Endocrinol Metab,2001,86(11):5273-5276.
[62]Karnafel W. Diabetic cardiomyopathy. Pathophysiology and clinical implications [J]. Przegl Lek,2000,57(4):9-11.
[63]Unger RH, Zhou YT, Qrci L. Regulation of fatty acid homeostasis in cells: novel role of leptin [J]. Proc Natl Acad Sci USA,1999,96(5):2327-2332.
[64]Unger RH. Weapons of lean body mass destruction:the role of ectopic lipids in the metabolic syndrome [J]. Endocrinology,2003,144(12):5159-5165.
[65]Duprez DA, Debuyzere MI, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients [J].Eur Heart J,1998,19(9):1371-1376.
[66]Brilla CG, Matsubara LS, Weber KT. Antifibrotic effect of spironolactone in preventingmyocardial fibrosis in systemetic arterial hypertension [J]. Am J Cardiol,1993,71(1):12-16.
[67]Sato A, Suzuki Y, Shibata H. Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients [J]. Hypertens Res,2000,23(1):25-31.
[68]Vogel G. Leptin:a trigger for puberty [J]. Science,1996,274(5292):1466-1467.
[69]Carcia Mayor RV, An drade MA, Rios M, et al. Serum leptin levels in normal children:relationship to age, gender, body mass index, pituitarygonadal hormones and pubertal stage [J]. Clin Endocrinol Metab,1997,82(9):849-855.
[70]孙长颢,于春媛,王舒然,等.儿童瘦素水平对青春发育的作用[J].中华预防医学杂志,2001,35(5)：293-296.
[71]Yu WH, Kimura M, Walezewska A, et al. Role of leptin in hypothalamic-pituitary functionJ [J]. Proc Natc Acad,1997,94(3):1023-1028.
[72]Wang Q, Santizo R, Baughman VL, et al. Estrogen provides neuroprotection in transient forebrain ischemia through perfusion-independent mechanisms in rats [J]. Stroke,1999,30:630-637.
[73]Alkayed NJ, Harukuni I, Kimes AS, et al. Gender-linked brain injury in experimental stroke [J]. Stroke,1998,29:159-165.
[74]Rusa R, Alkayed NJ, Crain BJ, et, al.17β-estradiol reduces stroke injury in estrogen-deficient female animals [J]. Stroke,1999,30:1665-1670.
[75]Green PS, Gridley KE, Simpkins JW. Nuclear estrogen receptor-independent neuroprotection by estratrienes:a novel interaction with glutathione [J]. Neuroscience,1998,84:7-10.
[76]Weaver CE, Park-Chung M, Gibbs TT, et al.17β-estradiol protects against NMDA-induced excitotoxicity by direct inhibition of NMDA receptors [J]. Brain Res,1997,761:338-341.
[77]Dubal DB, Shughrue PJ, Wilson ME, et al. Estradiol modulates bcl-2 in cerebral ischemia:a potential role for estrogen receptors [J]. J Neurosci,1999, 19:6385-6393.
[78]Mattson MP, Robinson N, Guo Q. Estrogens stabilize mitochondrial function and protect neural cells against the pro-apoptotic action of mutant presenilin-1 [J]. Neuroreport,1997,8:3817-3821.
[79]Behl C, Skutella T, Lezoualch F, et al. Neuroprotection against oxidative stress by estrogens:structure-activity relationship [J]. Mol Pharmacol,1997,51:535-541.
[80]Ayres S, Abplanalp W, Liu JH, et al. Mechanisms involved in the protective effect of estrodiol-17 beta on lipid peroxidation and DNA damage [J]. Am J Physiol,1998,274:1002-1008
[81]White RE, Darkow DJ, Lang JL. Estrogen relaxes coronary arteries by opening BK Ca channels through a cGMP-dependent mechanism [J]. Circ Res,1995, 77:936-942..
[82]Palmon SC, Williams MJ, Littleton-Kearney MT, et al. Estrogen increases cGMP in selected brain regions and in cerebral micro vessels [J]. J Cereb Blood Flow Metab,1998,18:1248-1252.
[83]McNeill AM, Kim N, Duckles SP, et al. Chronic estrogen treatment increases levels of endothelial nitric oxide synthase protein in rat cerebral microvessels [J]. Stroke,1999,30:2186-2190.
[84]Shi J, Panickar KS, Yang SH, et al. Estrogen attenuates over-expression of beta-amyloid precursor protein messager RNA in an animal model of focal ischemia [J]. Brain Res,1998,810:87-92
[85]Green PS, Gridley KE, Simpkins JW. Estradiol protects against beta-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells [J]. Neurosci Lett,1996,218:165-168.
[86]Honjo H, Tanaka K, Kashiwagi T, et al. Senile dementia-Alzheimer's type and estrogen [J]. Horm Metab Res,1995,27:204-207.
[87]Yaffe K, Sawaya G, Lieberburg I, et al. Estrogen therapy in postmenopausal women:effects on cognitive function and dementia [J]. JAMA,1998,279: 688-695.
[88]Berman KF, Schmidt PJ, Rubinow DR, et al. Modulation of cognition-specific cortical activity by gonadal steroids:a positron-emission tomography study in women [J]. Proc Natl Acad Sci USA,1997,94:8836-8841.
[89]Westendorp ICD, Veld BAI, Bots ML, et al. Hormone replacement therapy and intima-media thickness of the common carotid artery:the rotterdam study [J]. Stroke,1999,30:2561-2567.
[90]Petitti DB, Sidney S, Quesenberry CP Jr, et al. Ischemic stroke and use of estrogen and estrogen/progestogen as hormone replacement therapy [J]. Stroke, 1998,29:23-28.
[91]Houseknecht KL, Baile C A, Matteri R L, et al. The biology of leptin:a review [J]. Anim Sci,1998,76:1405-1420.
[92]Loffeda S, Yang S Q, Lin H Z, et al. Leptin regulates proinflammatory immune responses [J]. FASEB 1998,12(1):57-65.
[93]张丽.瘦素与脂肪肝[J].国外医学内分泌学分册,2004,24(1)：65-67.
[94]郑善德.瘦素与糖尿病动脉粥样硬化[J].国外医学内分泌学分册,2003,23(5)：322-324.
[95]Dicou E, Attoub S, Gressens P. Neuroprotective effects of leptin in vivo and in vitro [J].Neuvoreport.2001,12 (18):3947-3951.
[96]Soderberg S, Ahren B, Stegmayr B, et al. Leptin is risk marker for first-ever hemorrhagic stroke in a population-gased cohort [J]. Strok 1999,30 (2):328-337.
[97]金嘉林,田成功.瘦素的作用与瘦素抵抗[J].国外医学内分泌学分册,2002,22(2)：54-56.
[98]Biffl WL, Moore EE, Moore FA, et al. IL-6 in the injured patient marker of injury or mediator of inflammation [J]. Ann Surg,1996,224(5):647-664.
[99]Mckenting EG, Andrews PJD. Cytokines and adhesion molecules in acute brain injury [J]. Br J Anaesth,1998,80(1):77-84.
[100]Martin-Ancel A, Garcia-Alix A, Pascal Scalcedo D, et al. Interleukin-6 inthe cerebrospinal fluid after perinatal asphyxia is related to early and late neurological manifestations [J]. Pediatrics,1997,100(5):789-794.
[101]Campel IL, Ahraham CR, Mesliah E. Neurological diseases involved in transgenic mice by cerebral overpression of IL-6 [J]. Proc Natl Acad Sci USA, 1993,90(21):10061-10065.
[102]Rothlein R, Mainolfi EA, Czajkowski M, et al. A form of circulating ICAM-1 in human serum [J]. J Immunol,1991,147(11):3788-3793.
[103]Okada Y, Copeland BR, Mori E, et al. P-selec and intercellular adhesion molecular-1 expression after focal brain ischemia and reperfusion [J]. Stroke, 1994,25:202-221
[104]Ge H, Wen Y, Yang G, et al. Increased expression of intercellular adhesion molecule-1 in focal cerebral ischemia model [J]. chin Med J(Engl),2000, 113:75-79
[105]Vemuganti R, Dempsey RJ, Bowen KK. Inhibition of intercellular molecule-1 protein expression by antisense oligonucleotides is five after transient middle cerebral occlusion in rat [J]. Stroke,2004,35:179-184
[106]Shyu KG, Chang H, Lin CC, et al. Serum level of intercellular adhesion molecule-1 in patients with acute ischemia stroke [J]. J Neurol,1997, 244(2):90-93.
[107]Bitsch A, klene W, Murtada L, et al. A longitudinal prospective study of soluble adhesion molecules in acute stroke [J]. Stroke,1998,29(10):2129-2135.
[108]Matsuda S, Went C, Morita F, et al. Interleukin-6 prevents ischemia-induced learning disability and neuronal and synaptic loss in gerbils [J]. Neurosci lett, 1996,204, (1-2):109-112.
[109]Shibata M, Ueshima K, Harada M, et al. Effect of magnesium sulfate pretreatment and significance of matrix metalloproteinase-1 and interleukin-6 levels in coronary reperfusion therapy for patients with acute myocardial infarction [J]. Angiology,1999,50(7):573-582.
[110]Rosenberg GA, estrada EY. Dencoft JE. Matrix metaltoproteinase and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain [J]. Stroke,1998,29(10):2189-2195.
[111]Luheshi GN, Stefferl A, Turnbull AV, et al. Febrile response to tissue inflammation involves both peripheral and briar il-1 and TNF-alpha in the rat [J]. Am J Physiol,1997,272(3):862-868
[112]肖岚,黎杏群.白介素-6与脑缺血损伤[J].国外医学神经病学神经外科学分册,2000,27：258-261.
[113]Clark WM, Rinker LG, Lessov NS, et al. Time course of IL-6 Expression in experimental CNS ischemia [J]. Neurol Res,1999,1 (3):287-292.
[114]Anderson BO, Moore EE, Banerjee A. Phospholipase A2 regulates Critical inflammatory mediators of multiple organ failure [J]. J Surg Res,1994, 56(2):199-205.
[115]Ballou LR, Laulederkind SJ, Rosloniec EF, et al. Ceramide signaling andthe immune response [J]. Biochim Biophys Acta,1996,1301(3):273-287.
[116]Ishihara K, Hirano T. Molecular basis of the cells pecificity of cytokine action [J]. Biochim Biophys Acta,2002,1592(3):281-296.
[117]Ueland PM, Refsum H, Stabler SP, et al. Total homocysteine in plasma or serum:methods and clinical applications [J]. Clin Chem,1993,39:1764-1779.
[118]Macy PA, Homocysteine:predictor of thrombotic disease [J]. Clin Lab Sci. 2001,14(4):272-275.
[119]Obaidi AL, Stubbs P, Amersey R, et al. Acute and onvalescent changes in plasma homocysteine concentrations in acute coronary syndromes [J]. Heart, 2001,85(4):380-384.
[120]Markus HS, Ali N, Swaminathan R, et al. A common polymorphism in the methylen-etetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease [J]. Stroke,1997,28:1739-1743.
[121]Delport R, Ubbink JB, Vermaak WJ, et al. Hyperhomocysteinaemia in black patients with cerebral thrombosis [J]. QJM,1997,90:635-639.
[122]Ray JG, Harvey DT. Hyperhomocysteinemia as a cause of premature stroke in a young patient [J]. Arch Phys Med Rehabil,1998,79:343-345.
[123]Penix LP. Ischemic strokes secondary to vitamin B12 deficiency-induced hyper-homo-cystinemia [J]. Neurology,1998,51:622-624.
[124]Candito M, Bedoucha P, Mahagne MH, et al. Total plasma homocysteinedetermination by liquid chromatography before and after methionine loading. Results in cerebrovascular disease [J]. Chromatogr B Biomed Sci Appl,1997,692:213-216.
[125]Evers S, Koch&nbs P, Grotemeyer KH, et al. Features, symptoms, and neurophysiological findings in stroke associated with hyperho-mocysteinemia [J]. Arch Neurol,1997,54:1276-1282.
[126]Vila N, Deulofeu R, Chamorro A, et al. Plasma homocysteine levels in patients with ischemic cerebral infarction [J]. Med Clin (Barc),1998,110:605-608.
[127]Stamler JS, Osborne JA, Jaraki O, et al. Adverse vascular effect of homocysteine are modulated by endothelium-derived relaxing factor and relatedoxides of nitrogen [J]. J Clin Invest,1993,91:308-318.
[128]Rodgers GM, Conn MT. Homocysteine. an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells [J]. Blood,1990, 75:895-901.
[129]Franken DG, Boers GH, Blom HJ, et al. Treatment of mild hyperhomcysteinemia in vascular disease patients [J]. Arterioscler Thromb, 1994,14:465-470.
[130]Franken DG, Boers GH, Blom HJ, et al. Treatment of mild hyperhomcysteinemia in vascular disease patients [J]. Arterioscler Thromb, 1994,14:465-470.
[131]Glueck CJ, Shaw P, Lang JE, et al. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients [J]. Am J Cardiol,1995,75:132-136.
[132][] Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis [J]. Thromb Haemost,1999,81:165-176.
[133]Lalouschek W, Aull S, Serles W, et al. Genetic and nongenetic factors influencing plasma homocysteine levels in patients with ischemic cerebrovascular disease and healthy control subjects [J]. J Lab Clin Med,1999, 133:575-582.
[134]Boysen G, Brander T, Christensen H, et al. Homocysteine and risk of recurrent stroke [J]. Stroke,2003,34:1258-1261.
[135]Martinelli I, Battaglioli T, Pedotti P, et al. Hyperhomocysteine in cerebral vein thrombosis [J]. Blood,2003,102:1363-1366.
[136]McCully KS. Vascular pathology of homocysteine:implicat ions of the pathogenesis of arteiosclerosis [J]. Am J Pathol,1969,56(1):111-128.
[137]Perry IJ, Refsum H, Morris RW, et al, Prospective study of serum homocysteine concentration and risk of stroke in middle aged British men [J].Lancet,1995, 346(8987):1395-1398.
[138]Gao W, Tang J. Hyperhomocysteinemia:a new risk factor for many kinds of diseases:summary for national symposium on hyperhomocys teinemia and disease [J]. China Med J,1999,79(1):15-19.
[139]Rhoads GG, Dahlen G, Berg K, et al. LP(a) Lipoprotein as a risk factor f or myocardial infarction [J]. JAMA,1986,256:2540-2544.
[140]Durrington P N, Ishola M, Hunt L, et al. Apolipoprotein(a), Al, and B and p arental history in men with early onset ischemic heart disease [J]. Lancet,1988, 1:1070-1073.
[141]Hoefler G, Harnoncourt F, Paschke E, et al. Lipoprotein (a) a risk for myocardial infarction [J]. Arteriosclerosis,1988,8:398-401.
[142]Grenest J Jr, Jenner J L, McNamara J R, et al. Prevalence of lipoprotein(a) excess in coronary artery disease [J]. Am J Cardiol,1991,67:1039-1045.
[143]Murai A, Miyahara T, Fujimoto N, et al. Lipoprotein(a) as a risk factor for coronary heart disease and cerebral infarction [J]. Arterioscleros is,1986, 59:199-204.
[144]Jurgans G, Taddeipeters WC, Koeltringer P, et al. Lipoprote in(a) serum concentration and apolipoprotein(a) phenotype correlate with severit y andpresence of ischemic cerebrovascular disease [J]. Stroke,1995, 26:1841-1848.
[145]Suet Y, Thomas HKN, Siu TY, et al. Pattern of cerebral arterioscleros isin Hong Kong Chinese:severity in intracranial and extracranial vessels [J]. Stroke,1993, 24:779-784.
[146]刘芳玲,张葆樽,田玉旺,等.脑卒中患者颅内外动脉形态变化分析[J].中华医学杂志,1996,76：832-835.
[147]Glenner GG, Wong CW. Alzheimer's disease:initial report of the purification and characterization of a novel cerebrovascular amyloid protein [J]. Biochem Biophys Res Commun,1984,120:885-90
[148]Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD) Part Ⅱ Standardization of the neuropathologic assessment of Alzheimer's disease [J]. Neurology,1991, 41(4):479-486.
[149]Gandy S. Oxygen radical metabolism in vivo:molecular genetic models and assays [J].Neurobiology of Aging,1994,15(4):471-482.
[150]Wisniewski HM Beta protein fibrillogenesis and its impact on neuropil and microvessels [J]. Neurobiology of Aging,1993,14(6):665-666.
[151]Nakaumra T, Shoji M, Harigaya Y, et alβ-Amyloid protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease [J]. Ann Neurol,1994,36(6):903-911.
[152]Van Gool WA, Schenk DB, Bolhuis PA. Concentrations of β-Amyloid protein in cerebrospinal fluid increase with age in patients free from neurodegeneration disease [J].Neurosci lett,1994,172(3):122124.
[153]Pirttila P, Kim KS, Mehta PD, et al. Soluble amyloid β-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementiaand controls [J]. Neurol Sci,1994,127(7):90-95.
[154]Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of p-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease [J]. Ann Neurol,1995,38(4):643-648.
[155]Nitsh RM, Rebeck W, Deng M, et al. Cerebrospinal fluid levels of amyloid protein in Alzheimer's disease:Inverse correlation with severity of dementia and effect of Apolipoprotein E genotype [J]. Ann Neurol,1995,37(4):512-518.
[156]Crawford F, Suo Z, Fang C, et al.Characteristics of the in vitro uasoactivlty of beta-amgloid peptides[J].Exp Neurol,1998,150 (1):159-168.
[157]王爱民,周莹,肖波,等.脑梗塞患者血清高敏C反应蛋白水平的变化及其临床意义[J].临床神经病学杂志,2005,18(2)：153-154.
[158]华洁,牛国忠,李保华.急性脑血管疾病患者血清C反应蛋白测定的临床意义[J].中华急诊医学杂志,2003,12(7)：483-484.
[159]Adams JM, Cory S. The Bcl-2 protein family:arbiters of cell survival [J].Science,1998,281(5381):1322-1326.
[160]Youle RJ, Strasser A. The BCL-2 protein family:opposing activities that mediate cell death [J]. Nature Reviews Molecular Cell Biology,2008, 9(1):47-59.
[161]Alkayed NJ, Murphy SJ, Traystman RJ, et al. Neuroprotective effects of female gonadal steroids in reproductively senescent female rats [J]. Stroke,2000,31 (1):161-168.
[162]Andrea Cardona-Rossinyol, Margalida Mir, Victor Caraballo-Miralles, et al. Neuroprotective Effects of Estradiol on Motoneurons in a Model of Rat Spinal Cord Embryonic Explants [J]. Cellular and Molecular Neurobiology,2013, 33(3):421-432.
[163]Merchenthaler L, Dellovade TL, Shughrue PJ. Neuroprotection by Estrogen in Animal Models of Global and Focal ischemia [J]. Annals of the New York Academy of Sciences,2003,1007:89-100.
[164]Zhao H, Yenari MA, Cheng D, et al. Bcl-2 overexpression protects against neuron loss within the ischemic margin following experimental stroke and inhibits cytochrome c translocation and caspase-3 activity [J]. Journal of Neurochemistry,2003,85(4):1026-1036.
[165]Prakasa Babu P, Yoshida Y, Su M, et al. Immunohistochemical expressionof Bcl-2, bax and cytochrome c following focal cerebral ischemia and effect of hypothermia in rat [J]. Neuroscience Letters,2000,291(3):196-200.
[166]Roof RL, Hall ED. Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone [J]. J Neurotrauma,2000, 17(5):367-3881.
[167]Moscal L, Banka CL, Benjamin EJ. et al. Evidence-based guidelines for cardiovascular disease prevention in women 2007 [J]. Circulation,2007, 49(11):1230-1250.
[168]Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke:2002 Update [J]. Circulation, 2002,1069(3):388-391.
[169]Blaustein JD, Cytoplasmic estrogen receptors in rat brain:immunocytochemical evidence using three antibodies with distinct epitopes [J]. Endocrinology,1992, 131:1336-1342
[170]Liu R, Yang SH. Window of opportunity:Estrogen as a treatment for ischemic stroke [J]. Brain Res,2013,8993(13):76-80.
[171]Simpkins JW, Rajakumar G, Zhang YQ, et al. Estrogens may reduce mortality and ischemic damage caused by middle cerebral arteryocclusion in the female rat [J]. Neurosurg,1997,87:724-730.
[172]Toung TJ, Traystman RJ, Hum PD. Estrogen mediated neuroprotection after experimental stroke in male rats [J]. Stroke,1998,29(8):1666-1670.
[173]Nakamura T, Xi G, Keep RF, et al. Effects of endogenous and exogenous estrogen on intracerebral hemorrhage-induced brain damage in rats [J]. Acta Neurochir Suppl,2006,96:218-221
[174]Nelson HD, Walker M, Zakher B, et al. Menopausal hormone therapy for the primary prevention of chronic conditions:a systematic review to update the U.S. Preventive Services Task Force recommendations [J]. Ann Intern Med,2012, 157:104-113.
[175]Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement the-rapy on cardiovascular events in recently postmenopausal women: randomised trial [J]. BMJ,2012,345:6409.